Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Metrics to compare | LSTA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLSTAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.2x | −1.2x | −0.5x | |
PEG Ratio | −0.14 | 0.04 | 0.00 | |
Price/Book | 2.3x | 1.7x | 2.6x | |
Price / LTM Sales | 37.7x | 9.0x | 3.3x | |
Upside (Analyst Target) | 228.2% | 94.9% | 47.0% | |
Fair Value Upside | Unlock | 13.4% | 5.7% | Unlock |